Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02520297 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study of TRV130 for the Treatment of Fracture Pain
A Phase 2 study, sponsored by Trevena.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02520297: Clinical Trial Phase 2 study, sponsored by Trevena.
NCT02520297 is a Phase 2 study that was terminated before completion, run by Trevena. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02520297, a Phase 2 study, was terminated before completion, sponsored by Trevena.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the analgesic efficacy of TRV130 for moderate to severe acute pain in patients presenting to the emergency department (ED) with a suspected/known, unilateral, closed long bone fracture.
Primary Outcome
Pain intensity will be evaluated using an 11-point numeric pain rating scale administered over 3 hours
Interventions
- DRUG TRV130
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-10-20 |
| Est. Completion | 2015-10-23 |
| Phase | Phase 2 |
Why NCT02520297 stopped before completion
NCT02520297 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which TRV130 is the first listed.
NCT02520297 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02520297 about?
NCT02520297 is a clinical study titled "A Pilot Study of TRV130 for the Treatment of Fracture Pain". The primary objective is to evaluate the analgesic efficacy of TRV130 for moderate to severe acute pain in patients presenting to the emergency department (ED) with a suspected/known, unilateral, closed long bone fracture.
What is the current status of trial NCT02520297?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2015-10-20. Estimated completion is 2015-10-23.
What interventions are being tested in trial NCT02520297?
The interventions under investigation include: TRV130 (DRUG).
Who is sponsoring clinical trial NCT02520297?
This trial is sponsored by Trevena, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02520297's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI